Would seem more like:
'When we meet the conditions, we will uplist.'
I might add: 'When the right offer is made, we'll take it.'
Right now, this still young company with incredible potential is also an incredible takeover opportunity. The company doesn't want to be a stand alone but they have drug candidates to attract the interest of those who need their products to either replace their existing portfolio or to expand their existing portfolio. Having a 'top of the class' antibiotic is very attractive and there are additional applications to be explored. Having a potential stand alone multiple cancers solution is very attractive. Working in combination with other cancer drugs is equally attractive too. Having a psoriasis solution is very attractive. Having an autism solution is very attractive. Having much of their ongoing and soon to be initiated testing paid for by top research hospitals is rare. Having a shelf that may never be needed but there to continue their progress is excellent.
I don't see where multiple large companies won't be making offers. But that's me. When we think of how far the company has come in such an extraordinary short period of time, we also might consider impatience isn't our friend. It's fine to watch people take profits but the real profits are in front of us imo. The process of reaching the goals really aren't that far away and it fact shows how competent the management, the team and how good their science is. We continue to see higher highs and higher lows and all this is a good sign too.
I think we are in a good position to continue to see higher highs and higher lows as the company continues to roll out new drug candidates into human trials and advances in the trials currently in progress. IMO and I'm sure we'll be happy when B's final calculations are reported very soon.
Market Data 
Markets 
AI
